Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i guess the hgenq shares will be liquidated, delisted from the OTC and everyone gets nothing. this entire chapter 11 was a waste of time, the judges time, if the public is paying for his time, SEC time, DA time in this fake trial.
I don't get this need creditor approval to liquidate hgenq for what?
all the assets are sold and hgenq owns no assets. other the promissory from taran .
Why waste the 'OFFICIAL committe time with these legal paper work and bill the creditors more legal fees for nothing. and you need to let the judge know how much you are billing the clients.
Consider the Milestone Events:
+First (1st) FDA approval of a BLA
relating to Lenzilumab for CMML in
the United States, provided such
approval is granted within five (5)
years following the Closing Date.
The next three (3) FDA approvals of
a BLA relating to Lenzilumab for any
follow-on indication to CMML in the
United States provided such
approval(s) is granted within seven
(7) years following the Closing Date.
First (1st) Regulatory Approval of
any HGEN Product for a particular
Therapeutic Indication for
Lenzilumab in the United Kingdom,
Germany, France, Italy, Spain or
Australia (each, an “Approved
Country”), provided such approval is
granted within five (5) years
following the Closing Date."
There are a few other Milestone Events related to various net sales totals.
The Milestone Events can be seen on pages 55 and 56/95, linked here.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
What would it take to monetize these Milestone Events? It would take receiving a BLA from the FDA for CMML, and related indications in the US. I think Sanofi, with their deep pipeline of oncology products and processes, would be an excellent partner for us in oncology, once they complete the spin-off of their healthcare division in the coming months.
In other parts of the world, Regulatory approval of lenz from any Approved Country would qualify as a Milestone Event. I think SAMHRI will be of invaluable assistance to us in Australia.
How likely is it that Humanigen will get Regulatory authorization or approval to qualify for these Milestone Events?
The Creditors' Committee must think that not only is this likely, Humanigen may even accomplish more than currently indicated.
"The settlement amended the APA to, among other things, significantly expand the events that will trigger the contingent “Milestone Payments” and increase the amount of those payments under the APA."
page 4/5
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1075977&projectCode=HUM&docketNumber=235&source=DM
Any news of regulatory authorization or approval, or news regarding our restructuring, will signal Humanigen to recall their loaned shares.
you think that if the shares are 'worthless' why that ONE guy or one entity who owns 100 million shares is not selling any of his shares?
there is no shares for sale under .01. odd because he wants to go bankrupt by keeping his controlling shares. odd that he would not sell it for tax loss selling or capital loss.
As for liquidation, it allows the theives to walk clean and walk free. 'legally'
THE ""OFFICIAL"" COMMITTEE OF UNSECURED CREDITORS OF HUMANIGEN, INC is a fake committee comprised of fake creditors. 40 million of the 44 million 'claims' were fake and fraudulent creditor cliams and is 'disputed' claims.
The real owner of this company created these fake creditors so it can go bankrupt. and steal the 'assets' lenzi and say there was no bid..when they didn't solicit any bid. or the bid was restrictive and no evidence that company solicited any bid from any company.
the shares if dissolved could get delisted if liquidated and corporation doesn't exist anymore why even waste time writing a 10 page 'PLAN' to go bankrupty. waste of time. wasting court's time with this fake creditor claims,,and you don't the creditor 'committee' vote to go bankrupt. the creditor get nothing so why bother voting. it's the liquidation of the corporation that is the problem now. share can be delisted and cancelled. but who is still holding the 100 million shares for> and who owns it. Taran owns the 90% of the debtor shares. and owns he ip. creditors are fake. there is no committee.
it's obvious that this court in earth is incapable of carrying out 'justice' and this human court has dishonored the justice.
The final judgment will be made in the 'court of hell' for the very serious crimes that have been committed. crimes against humanity.
At this point it appears you may be right. My hopes are that something gets put together for the shell at least. Hopefully they can sell it, or if they abandon it then maybe a custodianship could happen here? If anything, positive happens and it comes off the expert market this will go multi-pennies.
This reminds me of one I traded over 5 years ago that was trading on the expert market, and nobody wanted it. I bought over a million shares at .0065 average. It exploded over a dollar within 5 months after me buying. I took a screenshot of my portfolio back at this time. I had sold half on the way up to these levels. This was the best one I had ever traded.
I am not saying this will happen here on HGEN, but anything is possible in the future:
Short interest is fake too.
Still as of march 28, 2024 the short interest in the OTC market shows 39,987 shares short.
Either the short interest fake or it's a autobot.
No human would not cover when the share price is .0001. and the short interest is still not close to zero.
Who is still running this stock? and the short is not a retail trader.
The short position actually INCREASED 951 shares from march 15,2024 to march 28, 2024 when it was trading between low of .000001 and .0005.
Why still have a short position or even add short at this price?
Proof that there is still market makers or autobots in the stock and the expert market is not unsolicited retail volume as they claim to be. and is not all retail customer volume it's market maker volume
you made an incredible trade for sure . its too bad durrant absconded with the loot
entire day was 300 shares
and 135 shares today until someone dumped 18,000 shares for .0000001. who sold that 18,000 shares?
The selling has completely dried up. zero volume
There is no sellers below 1 cents.
if you want to buy 1 million shares ,there is no sell orders to fill at 1 million shared buy order at .01
it was still possible to buy 1 million shares when it was trading at .02 before it went to OTC expert market.
You only win when you sell. I only posted on how good this looks in my portfolio when it moves just a tiny bit. I honestly did not expect it to hold those gains while its trading on the expert market.
If this ever comes off the expert market, then look out above! :) I only paid a little over a grand for all 4 million shares at a .00027 average, so I am not too concerned here if it fails.
Yes, you are right, in that I am definitely a Gambler and a lot of other things as well! LOL
the owner of taran think they can steal assets for free 'legally' pfff via the lenghty 240 documents of chapter 11 and 6 months for the fake claims to clear and gov't to clear. and they can walk free.
most corporations in the private sector just declare bankruptcy and take off to another country. and dissolve the corporations and not pay any money in legal fees to go bankrupt. it seems like they wanted to buy the assets or the LENZI ip patent for free. and wanted to complete the chapter 11 to bid for the assets and got it for free.
still wondering who actually owns the 90% of the shares? it seems like the real owner want to go bankrupt and liquidate. why waste that much money over 2 million in legal fees to make the shares worthless, it's just not logical
well by posting only when you win i believe you when you say your a gambler.
if i had 4 mm shares id be on the phone with durrant asking him about the last dump he took .
so what was it diarrhea or bricks?
LOL 😂😂😂 until this comes off the expert market these swings are expected .
how you doin today. can you post it pls
Ouch! What a change in balance from one trade today lol!
“Great things will be coming soon”
Someday….
Symbol Last Price $ Change $ Change % Qty # Price Paid $ Day's Gain $ Total Gain $ Total Gain % Value $
HGENQ 0.0033 0.0033 329,900.00% 4,000,000 0.00027 13,196.00 12,086.81 1,085.78% 13,200.00
this is the market
bid. : .0000001 100,000,000 shares
ask : .01 1000 shares
ask. : .05 1000 shares
ask : .10 1000 shares
ask: .25 1000 shares
ask: .50 1000 shares
notice the big gaps and no liquidity in the sell side.
only the machines in the exchange can bid. .0000001 most retail brokers minimum is .0001 bid
There was no sellers below .0033 or some autobot machine bid 300 shares.
and bought a whopping .99cent worth of assets.
why the sec ban level 2?
ie if you sold a antique object, antique dealers says it's a fake and offers you $10 for it, and later he sells for $10,000 a few days later as 'authentic' it's called fraud, and the seller can sue the antique dealer for ripping him off. for buying asset with trickery and ly it was a fake when it was not.
that schmuck insurance is so if the drug is successful former sellers of the drug cannot sue Taran for ripping them off and buying the ip lenzi molecule for nothing.. it's called the asset was sold way below 'fair value' in business.
Does the schmuck insurance still apply if the hgenq shares are 'liquidated' why even have smuck insurance hgenq who sold the worthless patent gets money if the drug is commercialized?
As previous owners of the patent LENZI, if the drug doesn't work and not effective why would Taran waste time lending 2 million to bid for a 'worthless' drug called lenzi that received more than 2.5 million in ip licensing fees from research firms for testing.
if the drug has no commercial use, the the molecule 'worthless so why bid for a worthless asset?
people were infected with corvid before there was a vaccine. you don't need a vaccine if a person can be cured with lenzi or anti-viral drug. The problem is the vaccine side effects is worse than the virus itself. that is the problem and over 20 billion of the vaccine was sold and billions in profits.
it's because if the lenzi works you don't need a vaccine. because a lot of people who get infected with flue or corvid recover without a vaccine. the problem is the cure is worse than then disease for some people taking the mRNA 'vaccine'
you body cannot make enough- t-cells or white blood cells fast enough when virus spreads too fast. with injection of these lenzi, drug sor anti-bacterial drugs it's synthetic boost in body defense until your body recovers on it's own.
a lot of these drugs in pharma just micmics or copy drugs in nature. the opium plant is natural..you can make synthetic opiod but why. nature does a good job of making opium for pain relief. same with white blood cells or T-cells , your body make those cells, people with AIDS have their t-cells reduced or damaged. with anti-viral drugs it boost your t-cell or what lenzi is. that critical moment can be life and death if a anti-viral drug is not injected in patient that is infected. a patient can die in days without a drug injection if in virus overtakes the body and t-cells cannnot absorb the viral cells and overrunned.
LENZI drug is blood cancer drug, with blood cancer, you immune system is suppressed like if you have AIDS. which is what happens when you have corvid, you immune system collapse. drug like LENZI is like hemo drugs like Draculat had blood disorder and had to drink human blood. lenzi is has same molecules as in human blood or other animal blood.
If this short squeezes beyond $15,000 from $0.000001 then that is a 1.5 Billion Bagger.
"The US government, in my opinion, is keeping lenz out of the covid market, to safeguard their Moderna investment, and misplaced faith in mRNA technology."
If that is true, as I firmly believe that it is, you must ask yourself how that could possibly have come about.
This authority for the US Government to interfere with the commercial development of covid vaccines, and to curtail the development of safe and effective therapeutics to combat covid, was vested in NIAID, when it was decided to resume the manufacture of bioweapons. In fact, Fauci got a 68% pay raise to resume the development of bioweapons, and their counter-measures.
Additional funding of gain function research began to be provided by other agencies and entities. The largest of these is the United States Agency for International Development ("USAID").
If you don't want to keep and study the entire video, watch it from minute marks 35 - 45:24
Ep. 16 RFK Jr. explains Ukraine, bio-labs, and who killed his uncle pic.twitter.com/RMr5VZVqSM
— Tucker Carlson (@TuckerCarlson) August 14, 2023
" I immediately remembered that Japan has a unique non-inflammatory diet and that this may account for the difference."
The US has 4.2% of the world's population, yet accounts for 17.4% of all covid deaths.
https://www.worldometers.info/world-population/
https://www.worldometers.info/coronavirus/
The Chinese collected national DNA databases, and it was reported that this was to aid in the design of a virus specifically targeting particular nations, such as the US.
I can see diet and obesity impacting covid cases differently from country to country, but not to this extent. However, I totally agree about the third mRNA jab "wrecking" the immune response system, which is why I want to see if lenz can help to restore the immune system in these vaccinees.
The FDA has a lot of power because if a drug is approved and has a patent, you are talking about billions in profits to investors.
As they say power corrupts, and absolute power corrupts absolutely.
Just with the 5 year data of the mRNA results ,the FDA would not approve moderna mRNA vaccine.
Another reason FDA would not approve a drug is there is no condition or drug needed.
Weight loss drug is a drug that is not needed. The side effect of weight loss drug is not enough to warrant risk of health risk.
Being overweight is not a disease. people can lose weight naturally and don't need drugs.
Like plastic surgery, most people don't need plastic surgery and some are just immoral to do as the people requesting has psychological issues who want weight loss or plastic surgery. FDA is not protecting the public or have the best interest of the public. when it's mandate is to protect the health of the public, a privillege granted to it by the 'public'
Why do you think FDA didn't approve a lot of drugs.
1. Side effects are too severed
2. Not effective doesn't work only improves conditions
And public cannot sue the gov't or sue the company who makes the experimental drug which didn't have the data for 5 years. As some conditions don't occur after 5-10 years as not everyone has same side effects from a drug. ie allergic reactions are unknown. when doing clinical drugs of new molecules like Lenzi. It does not matter. HGENQ shareholders don't own the patent and is being liquidated. May not even exist as a shell company for tax purpose or trading purposes.
how do you see ask at 0.25? which platform do you use?
the 'evil plan' is to liquidate..take the money and run and shut down operations.
that $3 million dollar lawsuit, the company has not paid any to the law firm as of april 4,2024. so way anyone who sent claims would have been paid. you a fool if you think humanigen would pay you a dime as the shareholder lawsuit was part of the scam to bankrupt the company. the claimants were fake too. there was no trial. or court hearing.
The 3 million dollar lawsuit has not been paid by humanigen so none of the .047/share settlement is paid as of april 4, 2024 which is 7 days ago. Why it took 1 years of litigation for this company to payout and insurance still has not paid. you drag it longer that 3 million minus legal fees has less than 1 million left in the pot. And reason the company wants to bail and liquidate company and not pay 3 milllion settlement. why pay. Insurance company has not wired the money to the law firm who supposedly was suppose to be receiving the money. but humanigen wants it and then wire it to the law firm who is the escrow and pay the .047/share. Insurance always wire the money to the company policy holder and then policy holder unless it gets permission to wire to law firm who claim the $3 million settlement.
Howdy, mates! Or should I say 'G,day, partners?'
"Hi Jay Booth, Aka Cowtown Jay,
There's been an update on Taran Pharma (Europe) Ltd in the last 24 hours:
Shareholders/Group Structure"
Management 'expects' the class 4,5 creditor which is the shareholders to get nothing in 'evil plan' to liquidate and shut down fraud operation. and needs the permission of the fake creditors and the Courts stamp of approval.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43443
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |